Viviana M Bimonte1,2,3, Francesco Marampon4, Ambra Antonioni2, Simona Fittipaldi5, Elisabetta Ferretti2, Richard G Pestell6, Mariaignazia Curreli2, Andrea Lenzi2, Giovanni Vitale7,8, Antonio Brunetti9, Silvia Migliaccio1, Antonio Aversa3. 1. Department of Movement, Human and Health Sciences, "Foro Italico" University, 00135 Rome, Italy. 2. Department of Experimental Medicine, "Sapienza" University of Rome, 00161 Rome, Italy. 3. Department of Experimental and Clinical Medicine, Magna Græcia University, 88100 Catanzaro, Italy. 4. Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University, 00161 Rome, Italy. 5. Department of Biomedicine and Prevention, "Tor Vergata" University, 00133 Rome, Italy. 6. Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, PA 19111, USA. 7. Department of Medical Biotechnologies and Translational Medicine, University of Milan, 20122 Milan, Italy. 8. Laboratory of Geriatric and Oncologic Neuroendocrinology Research, Istituto Auxologico Italiano, IRCCS, Cusano Milanino, 20095 Milan, Italy. 9. Department of Health Sciences, Magna Graecia University, 88100 Catanzaro, Italy.
Abstract
BACKGROUND: The androgen receptor (AR) plays a key role in normal prostate homeostasis and in prostate cancer (PCa) development, while the role of aromatase (Cyp19a1) is still unclear. We evaluated the effects of a treatment with Tadalafil (TAD) on both these proteins. METHODS: Androgen-sensitive human PCa cell line (LnCAP) was incubated with/without TAD (10-6 M) and bicalutamide (BCT) (10-4 M) to evaluate a potential modulation on cell proliferation, protein and mRNA expression of Cyp19a, AR and estrogen receptor-β (ERβ), respectively. RESULTS: TAD increased early AR nuclear translocation (p < 0.05, after 15 min of exposure), and increased AR transcriptional activity (p < 0.05) and protein expression (p < 0.05) after 24 h. Moreover, after 24 h this treatment upregulated Cyp19a1 and ERβ mRNA (p < 0.05 and p < 0.005 respectively) and led to an increase in protein expression of both after 48 h (p < 0.05). Interestingly, TAD counteracted Cyp19a1 stimulation induced by BCT (p < 0.05) but did not alter the effect induced by BCT on the AR protein expression. CONCLUSION: We demonstrate for the first time that TAD can significantly modulate AR expression and activity, Cyp19a1 and ERβ expression in PCa cells, suggesting a specific effect of these proteins. In addition, TAD potentiates the antiproliferative activity of BCT, opening a new clinical scenario in the treatment of PCa.
BACKGROUND: The androgen receptor (AR) plays a key role in normal prostate homeostasis and in prostate cancer (PCa) development, while the role of aromatase (Cyp19a1) is still unclear. We evaluated the effects of a treatment with Tadalafil (TAD) on both these proteins. METHODS: Androgen-sensitive human PCa cell line (LnCAP) was incubated with/without TAD (10-6 M) and bicalutamide (BCT) (10-4 M) to evaluate a potential modulation on cell proliferation, protein and mRNA expression of Cyp19a, AR and estrogen receptor-β (ERβ), respectively. RESULTS:TAD increased early AR nuclear translocation (p < 0.05, after 15 min of exposure), and increased AR transcriptional activity (p < 0.05) and protein expression (p < 0.05) after 24 h. Moreover, after 24 h this treatment upregulated Cyp19a1 and ERβ mRNA (p < 0.05 and p < 0.005 respectively) and led to an increase in protein expression of both after 48 h (p < 0.05). Interestingly, TAD counteracted Cyp19a1 stimulation induced by BCT (p < 0.05) but did not alter the effect induced by BCT on the AR protein expression. CONCLUSION: We demonstrate for the first time that TAD can significantly modulate AR expression and activity, Cyp19a1 and ERβ expression in PCa cells, suggesting a specific effect of these proteins. In addition, TAD potentiates the antiproliferative activity of BCT, opening a new clinical scenario in the treatment of PCa.
Authors: S Giannattasio; F Megiorni; V Di Nisio; A Del Fattore; R Fontanella; S Camero; C Antinozzi; C Festuccia; G L Gravina; S Cecconi; C Dominici; L Di Luigi; C Ciccarelli; P De Cesaris; A Riccioli; B M Zani; A Lenzi; R G Pestell; A Filippini; C Crescioli; V Tombolini; F Marampon Journal: J Endocrinol Invest Date: 2018-05-22 Impact factor: 4.256
Authors: Benedetta Fibbi; Annamaria Morelli; Linda Vignozzi; Sandra Filippi; Aravinda Chavalmane; Giulia De Vita; Mirca Marini; Mauro Gacci; Gabriella Barbara Vannelli; Peter Sandner; Mario Maggi Journal: J Sex Med Date: 2009-09-29 Impact factor: 3.802
Authors: E David Crawford; Axel Heidenreich; Nathan Lawrentschuk; Bertrand Tombal; Antonio C L Pompeo; Arturo Mendoza-Valdes; Kurt Miller; Frans M J Debruyne; Laurence Klotz Journal: Prostate Cancer Prostatic Dis Date: 2018-08-21 Impact factor: 5.554
Authors: Tiancheng Liu; Lisa Y Wu; Melody D Fulton; Jacqueline M Johnson; Clifford E Berkman Journal: Int J Oncol Date: 2012-10-04 Impact factor: 5.650
Authors: Emanuela Alessandra Greco; Cristina Antinozzi; Luigi Di Luigi; Antonio Aversa; Paolo Sgrò Journal: Int J Mol Sci Date: 2022-04-11 Impact factor: 6.208